Arizona Tribune - CBD Life Sciences Inc. (CBDL) Announces Smoking Scholars Bronx Dispensary as Major Distributor for High-Demand Dubai Mushroom Chocolate

SCOTTSDALE, ARIZONA / ACCESS Newswire / February 3, 2026 / CBD Life Sciences Inc. (OTC:CBDL), a fast-growing wellness and cannabinoid company focused on premium, trend-driven consumer products, today announced that Smoking Scholars, a well-established dispensary located in the Bronx, New York, has expanded its relationship with the Company to become a major distributor of CBDL's Dubai Mushroom Chocolate - one of the most in-demand functional wellness confections currently gaining traction across dispensary and specialty retail channels.

This expansion follows strong in-store performance of existing CBDL products already carried by Smoking Scholars, validating both consumer demand and retailer confidence. The addition of Dubai Mushroom Chocolate represents a strategic next step in maximizing shelf productivity and increasing average transaction value at the retail level.

Capitalizing on a Rapidly Expanding Consumer Trend

Functional mushroom products have transitioned from niche to mainstream, fueled by growing consumer awareness around wellness, mood, cognitive support, and lifestyle optimization. Mushroom-infused chocolates, in particular, have emerged as a top-performing category, combining indulgence with functionality - a key driver of repeat purchasing behavior.

Dubai Mushroom Chocolate sits directly at the intersection of premium confectionery, alternative wellness, and experiential products, making it an ideal offering for high-traffic urban dispensaries like Smoking Scholars.

Strategic Retail Placement with Immediate and Long-Term Upside

Smoking Scholars' Bronx location services a dense, high-volume consumer base in one of the most competitive retail markets in the country. Management believes this placement offers immediate revenue opportunity while simultaneously serving as a scalable blueprint for broader dispensary expansion throughout New York and other major metropolitan markets.

As CBDL continues to focus on products that demonstrate strong velocity, attractive margins, and repeat demand, management expects Dubai Mushroom Chocolate to play a meaningful role in driving incremental revenue and strengthening the Company's retail portfolio.

Executive Commentary

"This expansion reflects exactly how we are building CBDL - through performance-driven partnerships and products that consumers actively seek out," said Lisa Nelson, President & CEO of CBD Life Sciences Inc. "Smoking Scholars has already demonstrated strong results with our existing product line, and the addition of Dubai Mushroom Chocolate positions us to further capitalize on one of the fastest-growing segments in functional wellness. We believe this is a meaningful opportunity to increase retail revenue today while opening doors for additional distribution tomorrow."

Momentum That Opens Doors

With the functional mushroom sector experiencing sustained growth and increasing dispensary adoption, CBDL continues to execute on a strategy centered around real-world retail validation, disciplined expansion, and long-term shareholder value creation. Management anticipates that successful performance at Smoking Scholars will help accelerate conversations with additional dispensaries and specialty retailers seeking differentiated, high-demand products.

About CBD Life Sciences Inc. (CBDL)
CBD Life Sciences Inc. (OTC:CBDL) is a wellness and cannabinoid company focused on the development, marketing, and distribution of innovative products across the CBD, hemp, and functional wellness sectors. The Company is committed to expanding retail distribution, increasing revenue-generating opportunities, and delivering sustainable value for shareholders.

Follow our social media for the latest updates!
X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
Website: https://www.thecbdvault.com
IR Contact: [email protected]

Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.

Contact Information
Lisa Nelson
CEO
[email protected]
4802091720

SOURCE: CBD Life Sciences, Inc.

View the original press release on ACCESS Newswire

P.A.Mendoza--AT